VRM
IPHA

Vectors Research Management’s Innate Pharma IPHA Stock Holding History

Vectors Research Management’s Portfolio IPHA Stock Details IPHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-1,000
Closed -$5.32K – 603
2021
Q3 		$6K Buy
+1,000
New +$4.31K ﹤0.01% 403

Other funds holding IPHA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return
SCM
Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Vectors Research Management's IPHA Position: Q4 2021 in Review

Vectors Research Management sold out of Innate Pharma (IPHA) in Q4 2021, closing a stake of 1,000 shares — an estimated $5.32K sold.

Vectors Research Management first reported a position in IPHA in Q3 2021 and held it in 1 quarter. The position peaked at $6K in Q3 2021. 16 funds tracked by Wall St. Rank hold IPHA as of Q4 2021.

  • Vectors Research Management reported no remaining Innate Pharma position as of Q4 2021 after selling out during the quarter.
  • Vectors Research Management sold 1,000 Innate Pharma shares in Q4 2021, an estimated $5.32K.
  • Vectors Research Management first reported a position in Innate Pharma in Q3 2021 and held it in 1 quarter.
  • Vectors Research Management's Innate Pharma position peaked at $6K in Q3 2021.
  • 16 funds tracked by Wall St. Rank held Innate Pharma as of Q4 2021.

Based on Vectors Research Management's 13F filing for Q4 2021, filed 15 Feb 2022.